This trial is active, not recruiting.

Condition essential hypertension
Treatment ramipril
Phase phase 4
Sponsor Pacific Pharmaceuticals
Start date June 2006
End date June 2007
Trial size 86 participants
Trial identifier NCT00366119, RMN-P01


The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Reduction of DBP(diastolic blood pressure)
time frame:

Secondary Outcomes

Reduction of SBP(systolic blood pressure)
time frame:
Percentage of patients with Dcrease of BP(blood pressure)
time frame:
Percentage of patients with a Normalization of BP(blood pressure)
time frame:
Artery stiffness(chang of pulse wave velocity)
time frame:
Left ventricular diastolic function
time frame:
Change of BNP
time frame:
Change of CRP
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - mild and moderate essential hypertension (90mmHg≤DBP≤110mmHg) Exclusion Criteria: - 180mmHg≤SBP - If differences greater than 20mmHg for SBP and 10mmHg for DBP between both arms are present on 3 consecutive readings - If differences greater than 20mmHg for SBP and 10mmHg for DBP are present on 3 consecutive readings - impaired hepatic function - imapaired renal function - angioedema - aortic valvular stenosis or obstrcutive ejection disorder - primary hyperaldosteronism - renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis - severe respiratory disease - congestive heart failure( New York Association functional class Ⅲ or Ⅳ) - malignant hypertension - labile angina pectoris or myocardial infarction in the last 3 months before study entry

Additional Information

Official title Phase 4 Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Ramiprin Tab. in Essential Hypertension
Principal investigator HyoSoo Kim, Ph.D in MD
Trial information was received from ClinicalTrials.gov and was last updated in March 2007.
Information provided to ClinicalTrials.gov by Pacific Pharmaceuticals.